摘要
目的观察清胃祛湿方治疗脾胃虚弱型幽门螺杆菌(Hp)相关性慢性胃炎的临床价值及作用机制。方法回顾性分析2016年7月—2018年9月广州中医药大学第四临床医学院收治的134例Hp相关性慢性胃炎患者的临床资料,按照治疗方法的不同分为研究组和对照组,每组67例。对照组患者给予常规西药疗法;研究组患者给予清胃祛湿方。比较分析两组患者治疗后的临床疗效、临床证候积分及Hp根除率,同时检测血清表皮生长因子(EGF)及胃蛋白酶原(PG)的水平。结果研究组患者治疗后临床证候积分低于对照组(P<0.05),而临床疗效总有效率、Hp根除率高于对照组患者(P<0.05)。两组患者治疗后血清PGⅠ水平高于治疗前,而血清EGF、PGⅡ水平低于治疗前(P<0.05)。研究组患者治疗后血清PGⅠ水平高于对照组,血清EGF、PGⅡ水平低于对照组(P<0.05)。结论清胃祛湿方治疗脾胃虚弱型Hp相关性慢性胃炎疗效肯定,其不仅可以提高HP根除率、改善患者临床症状及体征,而且对胃黏膜损伤有保护作用。对促进胃部功能恢复,提高患者预后生活质量有积极意义。
Objective To observe the clinical value and mechanism of Qingwei Qushi Decoction in treating chronic gastritis associated with helicobacter pylori (HP) of spleen and stomach weakness. Methods The clinical data of 134 patients with HP-related chronic gastritis admitted to our hospital were retrospectively analyzed. The patients were divided into study group (n = 67) and control group (n = 67) according to different treatment methods. The patients in the control group were given routine western medicine therapy, while the patients in the study group were given Qingwei Qushi Fang. The clinical efficacy, clinical syndrome score and HP eradication rate of the two groups were compared and analyzed. The levels of serum epidermal growth factor (EGF) and pepsinogen (PG) were also detected. Results After treatment, the clinical syndrome scores of the study group were significantly lower than those of the control group (P < 0.05). After treatment, the total effective rate of the study group (89.55%) was significantly higher than that of the control group (70.15%)(P < 0.05). After treatment, the eradication rate of HP in the study group (77.61%) was significantly higher than that in the control group (52.24%)(P < 0.05). After treatment, the levels of serum PGI in both groups were significantly higher than those before treatment, and the levels of serum EGF and PGII were significantly lower than those before treatment (P < 0.05);after treatment, the levels of serum PGI in the study group were significantly higher than those in the control group, and the levels of serum EGF and PGII were significantly lower than those in the control group (P < 0.05). Conclusions Qingwei Qushi Decoction can obtain definite curative effect in treating HP-related chronic gastritis of Spleen-stomach weakness type. It can not only improve HP eradication rate, clinical symptoms and signs of patients, but also protect gastric mucosal injury. It has positive significance in promoting the recovery of gastric function and improving the prognosis quality of life of patients.
作者
梁艺钟
林德荣
郭绍举
李健
Yi-zhong Liang;De-rong Lin;Shao-ju Guo;Jian Li(the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou,Guangdong 510000, China;Shenzhen TCM Hospital, Shenzhen, Guangdong 518000, China)
出处
《中国现代医学杂志》
CAS
2019年第16期103-107,共5页
China Journal of Modern Medicine
关键词
胃炎
螺旋杆菌
幽门
药理作用分子作用机制
gastritis
helicobacter pylori
molecular mechanisms of pharmacological action